1. Home
  2. RFL vs CUE Comparison

RFL vs CUE Comparison

Compare RFL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.35

Market Cap

61.1M

Sector

Finance

ML Signal

HOLD

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$0.30

Market Cap

27.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFL
CUE
Founded
2017
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.1M
27.1M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
RFL
CUE
Price
$1.35
$0.30
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.00
AVG Volume (30 Days)
77.8K
355.6K
Earning Date
03-30-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
28.28
35.14
EPS
N/A
N/A
Revenue
$917,000.00
$9,287,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$25.00
P/E Ratio
N/A
N/A
Revenue Growth
43.96
69.16
52 Week Low
$1.12
$0.23
52 Week High
$3.19
$1.17

Technical Indicators

Market Signals
Indicator
RFL
CUE
Relative Strength Index (RSI) 62.90 44.87
Support Level $1.30 $0.28
Resistance Level $1.44 $0.36
Average True Range (ATR) 0.08 0.02
MACD 0.02 0.00
Stochastic Oscillator 49.99 40.41

Price Performance

Historical Comparison
RFL
CUE

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Share on Social Networks: